About CUTIA-B Company

Established in 2019, we are a biopharmaceutical company driven by R&D and focusing on dermatology. We are committed to developing comprehensive solutions in a wide range of dermatology treatment and care markets to meet the ever-changing and diverse needs of patients and consumers. We have established a broad product portfolio targeting the four main areas of the broad dermatology treatment and care market, namely hair diseases and care, skin diseases and care, epidermal anesthesia, and topical fat accumulation management drugs. We also distribute several commercial products developed by overseas partners, and have launched several products in China. We are one of the few players with comprehensive comprehensive capabilities in the broad dermatology treatment and care market in China. We are customer-centric to improve candidate products and extend our comprehensive capabilities across the broad dermatology treatment and care industry value chain. Our platform covers everything from identifying requirements, developing core technology, managing clinical trials and early stages of product registration to product production and marketing. Our proprietary CATAME technology platform enables topical or transdermal administration of drugs by developing micron and nanoscale particles, evaluating the quality and stability of formulations, and performing dermal pharmacokinetic analysis. Our platform also helps design the most suitable dosage form, which is the key to specificity and successful administration. Through this platform, we have built a competitive product line for creams, sprays, ointments, aerosol foams, and other dosage forms.